These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

410 related items for PubMed ID: 17011381

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Transdermal oxybutynin: sticking to the facts.
    Cartwright R, Cardozo L.
    Eur Urol; 2007 Apr; 51(4):907-14; discussion 914. PubMed ID: 17157979
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder.
    Staskin DR, Robinson D.
    Expert Opin Pharmacother; 2009 Dec; 10(18):3103-11. PubMed ID: 19954278
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.
    Herschorn S, Stothers L, Carlson K, Egerdie B, Gajewski JB, Pommerville P, Schulz J, Radomski S, Drutz H, Barkin J, Paradiso-Hardy F.
    J Urol; 2010 May; 183(5):1892-8. PubMed ID: 20303119
    [Abstract] [Full Text] [Related]

  • 9. Evolution of transdermal oxybutynin in the treatment of overactive bladder.
    Sahai A, Mallina R, Dowson C, Larner T, Khan MS.
    Int J Clin Pract; 2008 Jan; 62(1):167-70. PubMed ID: 18173821
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity.
    Cartwright PC, Coplen DE, Kogan BA, Volinn W, Finan E, Hoel G.
    J Urol; 2009 Oct; 182(4):1548-54. PubMed ID: 19683731
    [Abstract] [Full Text] [Related]

  • 12. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence.
    Davila GW, Daugherty CA, Sanders SW, Transdermal Oxybutynin Study Group.
    J Urol; 2001 Jul; 166(1):140-5. PubMed ID: 11435842
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
    Kennelly MJ, Lemack GE, Foote JE, Trop CS.
    Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
    Staskin DR, Dmochowski RR, Sand PK, Macdiarmid SA, Caramelli KE, Thomas H, Hoel G.
    J Urol; 2009 Apr; 181(4):1764-72. PubMed ID: 19233423
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome.
    Sand PK, Davila GW, Lucente VR, Thomas H, Caramelli KE, Hoel G.
    Am J Obstet Gynecol; 2012 Feb; 206(2):168.e1-6. PubMed ID: 21963104
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial.
    Sand PK, Goldberg RP, Dmochowski RR, McIlwain M, Dahl NV.
    Am J Obstet Gynecol; 2006 Dec; 195(6):1730-5. PubMed ID: 17132474
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.